ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 155 filers reported holding ASCENDIS PHARMA A/S in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,456,896 | -12.2% | 60,221 | 0.0% | 0.01% | -16.7% |
| Q4 2022 | $7,354,791 | +22.5% | 60,221 | +3.6% | 0.01% | +20.0% |
| Q3 2022 | $6,002,000 | +26.2% | 58,127 | +13.6% | 0.01% | +42.9% |
| Q2 2022 | $4,757,000 | -18.5% | 51,174 | +1.7% | 0.01% | -12.5% |
| Q1 2022 | $5,836,000 | +17.4% | 50,305 | +36.2% | 0.01% | +33.3% |
| Q4 2021 | $4,970,000 | -11.5% | 36,943 | +4.8% | 0.01% | -33.3% |
| Q3 2021 | $5,618,000 | +87.5% | 35,248 | +54.7% | 0.01% | +125.0% |
| Q2 2021 | $2,997,000 | +10.4% | 22,780 | +8.2% | 0.00% | 0.0% |
| Q1 2021 | $2,714,000 | -57.1% | 21,057 | -44.4% | 0.00% | 0.0% |
| Q4 2020 | $6,320,000 | +105.5% | 37,894 | +95.5% | 0.00% | -20.0% |
| Q3 2020 | $3,076,000 | +17.3% | 19,388 | +9.4% | 0.01% | 0.0% |
| Q2 2020 | $2,622,000 | +52.4% | 17,729 | +21.9% | 0.01% | +25.0% |
| Q1 2020 | $1,720,000 | -14.7% | 14,538 | +0.3% | 0.00% | +33.3% |
| Q4 2019 | $2,016,000 | +44.6% | 14,492 | 0.0% | 0.00% | +50.0% |
| Q3 2019 | $1,394,000 | – | 14,492 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |